Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Ruzicka

Showing results (21-30 of 314) with videos related to

Pageof 32
Sort By:
Acta Dermato-Venereologica|June 21, 2003
Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivityRoland Kruse, Thomas Ruzicka, Markus Grewe
Autoimmunity Reviews|May 17, 2005
Socioeconomic factors in lupus erythematosusStephan Meller, Bernhard Homey, Thomas Ruzicka
Annals of Dermatology|May 12, 2012
Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin diseaseMarkus Reinholz, Thomas Ruzicka, Jürgen Schauber
MMW Fortschritte Der Medizin|April 17, 2016
[Acrodermatitis chronica atrophicans]Diana Wittmann, Markus Heppt, Thomas Ruzicka
European Journal of Dermatology : EJD|September 2, 2003
Potential future dermatological indications for tacrolimus ointmentThomas Ruzicka, Till Assmann, Mark Lebwohl
Archives of Dermatological Research|September 18, 2008
Topical calcineurin inhibitors in cutaneous lupus erythematosusMiklós Sárdy, Thomas Ruzicka, Annegret Kuhn
Allergy, Asthma & Immunology Research|May 3, 2013
Vitamin d, the cutaneous barrier, antimicrobial peptides and allergies: is there a link?Elisabeth Roider, Thomas Ruzicka, Jürgen Schauber
MMW Fortschritte Der Medizin|December 15, 2011
[A triumph in treatment: botulinum toxin in medicine]Florian Heinen, Thomas Brandt, Thomas Ruzicka
Experimental Dermatology|April 2, 2014
Face-to-face with anti-inflammatory therapy for rosaceaSuzanna Salzer, Thomas Ruzicka, Jürgen Schauber
Journal of the American Academy of Dermatology|July 29, 2004
Therapy for severe necrotizing vasculitis with infliximabRenz Mang, Thomas Ruzicka, Helger Stege
Pageof 32

Showing results (21-30 of 314) with videos related to

Sort By:
Pageof 32
Acta Dermato-Venereologica|June 21, 2003
Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivityRoland Kruse, Thomas Ruzicka, Markus Grewe
Autoimmunity Reviews|May 17, 2005
Socioeconomic factors in lupus erythematosusStephan Meller, Bernhard Homey, Thomas Ruzicka
Annals of Dermatology|May 12, 2012
Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin diseaseMarkus Reinholz, Thomas Ruzicka, Jürgen Schauber
MMW Fortschritte Der Medizin|April 17, 2016
[Acrodermatitis chronica atrophicans]Diana Wittmann, Markus Heppt, Thomas Ruzicka
European Journal of Dermatology : EJD|September 2, 2003
Potential future dermatological indications for tacrolimus ointmentThomas Ruzicka, Till Assmann, Mark Lebwohl
Archives of Dermatological Research|September 18, 2008
Topical calcineurin inhibitors in cutaneous lupus erythematosusMiklós Sárdy, Thomas Ruzicka, Annegret Kuhn
Allergy, Asthma & Immunology Research|May 3, 2013
Vitamin d, the cutaneous barrier, antimicrobial peptides and allergies: is there a link?Elisabeth Roider, Thomas Ruzicka, Jürgen Schauber
MMW Fortschritte Der Medizin|December 15, 2011
[A triumph in treatment: botulinum toxin in medicine]Florian Heinen, Thomas Brandt, Thomas Ruzicka
Experimental Dermatology|April 2, 2014
Face-to-face with anti-inflammatory therapy for rosaceaSuzanna Salzer, Thomas Ruzicka, Jürgen Schauber
Journal of the American Academy of Dermatology|July 29, 2004
Therapy for severe necrotizing vasculitis with infliximabRenz Mang, Thomas Ruzicka, Helger Stege
Pageof 32